u/TheRealDrLeeMD

Physician here. The FDA dropped a proposed rule May 1st that would formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list. If finalized, 503B pharmacies can't compound these — period. Not during shortages, not ever.

What this means for you right now: nothing changes today. This is a proposed rule. Public comment period runs through June 29, 2026. If you're currently on a compounded GLP-1 from a legitimate 503B facility, your supply isn't cut off tomorrow.

What it means long-term: the writing has been on the wall since the shortage ended. 503A pharmacies (patient-specific prescriptions from a licensed prescriber) operate under a completely different legal framework and are NOT affected by this rule. The FDA is targeting large-scale outsourcing facilities, not your doctor writing you a script.

If your provider can't explain the difference between 503A and 503B, that's a red flag.

The public comment period matters. If you've had a positive experience with compounded GLP-1s and want your voice heard, comments.regulations.gov is where you go. Deadline June 29.

I've been prescribing compounded GLP-1s since 2021 and have treated thousands of patients. Happy to answer questions about what this means for your specific situation.

If you've been on compounded semaglutide or tirzepatide, you've probably seen the news. Multiple 503(b) outsourcing facilities are ceasing production or being shut down by the FDA. Patients are losing access to medications that were working for them, and a lot of people are panicking.

I run a telemedicine practice and treat thousands of GLP-1 patients. Here's what I'm telling mine:

**What's actually happening:** The FDA is tightening enforcement on 503(b) compounding facilities. Some are shutting down voluntarily, others are being forced out. This does NOT mean all compounded GLP-1s are going away — but it does mean the landscape is shifting fast.

**What this means for you:** If your pharmacy closes, your prescription doesn't transfer automatically. You need a provider who has relationships with pharmacies that are still operating, compliant, and shipping legitimate product.

**What to look for in a new provider or pharmacy:**

* Are they using a licensed, FDA-registered 503(a) or 503(b) pharmacy?
* Is the product third-party tested?
* Is a real physician reviewing your case, or is it a prescription mill?
* Can they ship to your state?

**What to watch out for:** The 503(b) shutdowns are pushing patients toward subscription telehealth platforms and DTC weight loss companies. Some of these are backed by venture capital, not physicians. Before you sign up, ask yourself:

Are you seeing the same doctor each time, or a random provider from a rotating network? Is the medication coming from a vetted pharmacy, or are they white-labeling product and marking it up 3-4x? Are you locked into a monthly subscription you can't cancel easily? Do they actually adjust your dose based on your response, or is everyone on the same cookie-cutter protocol?

A lot of these platforms spent more money on Instagram ads than on clinical infrastructure. They're designed to acquire patients fast, not treat them well. When the compounding landscape shifts again — and it will — those companies pivot or shut down. Your provider shouldn't be a startup that might not exist next year.

I've been treating GLP-1 patients for years. I'm not going anywhere. If you want a real physician who actually manages your care and ships legitimate, safe, quality compounded medication —